Items where Subject is "Immunotherapy"

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Authors | Item Type
Number of items at this level: 20.

Paper

Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., Vonderheide, R. H., Pittet, M. J., Jain, R. K., Zou, W., Howcroft, T. K., Woodhouse, E. C., Weinberg, R. A., Krummel, M. F. (May 2018) Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med, 24 (5). pp. 541-550. ISSN 1078-8956

Bradley, Sherille D, Talukder, Amjad H, Lai, Ivy, Davis, Rebecca, Alvarez, Hector, Tiriac, Herve, Zhang, Minying, Chiu, Yulun, Melendez, Brenda, Jackson, Kyle R, Katailiha, Arjun, Sonnemann, Heather M, Li, Fenge, Kang, Yaan, Qiao, Na, Pan, Bih-Fang, Lorenzi, Philip L, Hurd, Mark, Mittendorf, Elizabeth A, Peterson, Christine B, Javle, Milind, Bristow, Christopher, Kim, Michael, Tuveson, David A, Hawke, David, Kopetz, Scott, Wolff, Robert A, Hwu, Patrick, Maitra, Anirban, Roszik, Jason, Yee, Cassian, Lizée, Gregory (October 2020) Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Nature Communications, 11 (1). p. 5332. ISSN 2041-1723

Connell, C. M., Raby, S., Beh, I., Flint, T., Williams, E., Fearon, D. T., Jodrell, D. I., Janowitz, T. (July 2017) Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes. Ann Oncol, 28 (7). pp. 1678-1679. ISSN 0923-7534

Connell, C. M., Raby, S. E. M., Beh, I., Flint, T. R., Williams, E. H., Fearon, D. T., Jodrell, D. I., Janowitz, T. (January 2018) Cancer Immunotherapy Trials Underutilize Immune Response Monitoring. Oncologist, 23 (1). pp. 116-117. ISSN 1083-7159

Dancsok, A. R., Setsu, N., Gao, D., Blay, J. Y., Thomas, D., Maki, R. G., Nielsen, T. O., Demicco, E. G. (July 2019) Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. Mod Pathol, 32 (12). pp. 1662-1785. ISSN 0893-3952

Dancsok, A. R., Gao, D., Lee, A.F., Steigen, S.E., Blay, J.Y., Thomas, D.M., Maki, R.G., Nielsen, T. O., Demicco, E. G. (April 2020) Tumor-associated Macrophages and Macrophage-Related Immune Checkpoint Expression in Sarcomas. Oncoimmunology, 9 (1). p. 1747340. ISSN 2162402X,

Fearon, D. T. (March 2017) Immune-Suppressing Cellular Elements of the Tumor Microenvironment. Annual Review of Cancer Biology, 1 (1). pp. 241-255. ISSN 2472-3428

Fessas, P., Lee, H., Ikemizu, S., Janowitz, T. (April 2017) A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol, 44 (2). pp. 136-140. ISSN 0093-7754

Flint, T. R., Jones, J. O., Ferrer, M., Colucci, F., Janowitz, T. (March 2018) A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy. Semin Oncol. ISSN 0093-7754

Ghosh, D., Venkataramani, P., Nandi, S., Bhattacharjee, S. (January 2019) CRISPR-Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics. Cancer Cell Int, 19. p. 12. ISSN 1475-2867 (Print)1475-2867

Janowitz, T., Welsh, S. J., Zaki, K., Mulders, P., Eisen, T. (August 2013) Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin Oncol, 40 (4). pp. 482-91. ISSN 0093-7754

Janowitz, Tobias, Kleeman, Sam, Vonderheide, Robert H (April 2021) Reconsidering Dexamethasone for Antiemesis when Combining Chemotherapy and Immunotherapy. The Oncologist, 26 (4). pp. 269-273. ISSN 1083-7159

Maiorino, L., Egeblad, M. (August 2019) Tumours pick the path to cancer inflammation. Nat Cell Biol, 21 (9). pp. 1055-1057. ISSN 1465-7392

Rozenblit, M., Hendrickx, W., Heguy, A., Chiriboga, L., Loomis, C., Ray, K., Darvishian, F., Egeblad, M., Demaria, S., Marincola, F. M., Bedognetti, D., Adams, S. (June 2019) Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. Sci Rep, 9 (1). p. 8572. ISSN 2045-2322

Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T. H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., Ziv, E., Culhane, A. C., Paull, E. O., Sivakumar, I. K. A., Gentles, A. J., Malhotra, R., Farshidfar, F., Colaprico, A., Parker, J. S., Mose, L. E., Vo, N. S., Liu, J., Liu, Y., Rader, J., Dhankani, V., Reynolds, S. M., Bowlby, R., Califano, A., Cherniack, A. D., Anastassiou, D., Bedognetti, D., Rao, A., Chen, K., Krasnitz, A., Hu, H., Malta, T. M., Noushmehr, H., Pedamallu, C. S., Bullman, S., Ojesina, A. I., Lamb, A., Zhou, W., Shen, H., Choueiri, T. K., Weinstein, J. N., Guinney, J., Saltz, J., Holt, R. A., Rabkin, C. E., Lazar, A. J., Serody, J. S., Demicco, E. G., Disis, M. L., Vincent, B. G., Shmulevich, L. (April 2018) The Immune Landscape of Cancer. Immunity, 48 (4). pp. 812-830. ISSN 1074-7613

Verspoor, F. G. M., Mastboom, M. J. L., Hannink, G., Maki, R. G., Wagner, A., Bompas, E., Desai, J., Italiano, A., Seddon, B. M., van der Graaf, W. T. A., Blay, J. Y., Brahmi, M., Eberst, L., Stacchiotti, S., Mir, O., van de Sande, M. A. J., Gelderblom, H., Cassier, P. A. (October 2019) Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. Sci Rep, 9 (1). p. 14551. ISSN 2045-2322

Book Section

Xu, M., Ergin, I., Beyaz, S. (April 2020) Advances in Diagnostic Procedures and Their Applications in the Era of Cancer Immunotherapy. In: Immunotherapy. Springer, pp. 37-50.

Conference or Workshop Item

Almeida, Ana S, Kees, Tim, Egeblad, Mikala (October 2015) Modulating innate-adaptive immune cell interactions to achieve tumor rejection. In: AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter.

Burgess, M. A., Bolejack, V., Schuetze, S., Van Tine, B. A., Attia, S., Riedel, R. F., Hu, J. S., Davis, L. E., Okuno, S. H., Priebat, D. A., Movva, S., Reed, D. R., D'Angelo, S. P., Lazar, A. J., Keung, E. Z. Y., Reinke, D. K., Baker, L. H., Maki, R. G., Patel, S., Tawbi, H. A. H. (May 2019) Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts. In: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO).

Yan, Ran, Wang, Zhikai, Gao, Ya, Janowitz, Tobias, Fearon, Douglas T (May 2020) Immunogenicity and the CXCL12-coat control T cell accumulation in murine pancreatic cancer. In: UNSPECIFIED. (Unpublished)

This list was generated on Fri Sep 17 19:22:51 2021 EDT.
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving